To the Editor Compared with placebo, the nonadrenergic vasopressor angiotensin II was shown to increase mean arterial pressure after 3 hours in patients with vasodilatory shock in the Angiotensin II for the Treatment of High-Output Shock (ATHOS-3) trial (primary end point).¹ In addition, angiotensin II also reached the secondary goal of a greater reduction in the cardiovascular Sequential Organ Failure Assessment (SOFA) score after 48 hours vs placebo. As a consequence, research with angiotensin II continued and it was approved by the US Food and Drug Administration.

中文翻译：

---

Selepressin 用于感染性休克患者。

致编辑与安慰剂相比，在血管紧张素 II 治疗高输出量休克 (ATHOS-3) 试验（主要终点）中，非肾上腺素能血管加压剂血管紧张素 II 显示血管扩张性休克患者 3 小时后平均动脉压升高. ¹此外，与安慰剂相比，血管紧张素 II 还达到了次要目标，即 48 小时后心血管顺序器官衰竭评估 (SOFA) 评分进一步降低。因此，血管紧张素 II 的研究继续进行，并获得了美国食品和药物管理局的批准。